A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT01056159
- Locations
- 🇺🇸
Teva Clinical Study Site, Lake Oswego, Oregon, United States
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1047
- Registration Number
- NCT01047319
- Locations
- 🇺🇸
Teva Investigational Site 1267, Homewood, Alabama, United States
🇺🇸Teva Investigational Site 1275, Atlanta, Georgia, United States
🇺🇸Teva Investigational Site 1272, Pasadena, California, United States
Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01032486
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
Phase 3
Completed
- Conditions
- Seasonal Allergic RhinitisHay Fever
- Interventions
- Drug: Placebo Nasal Aerosol
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT01024608
- Locations
- 🇺🇸
Teva Clinical Trial Site, Waco, Texas, United States
Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients
Phase 4
Terminated
- Conditions
- Stable Renal Transplant Recipients
- Interventions
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT00991510
Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method
Phase 4
Completed
- Conditions
- Growth Hormone Deficiency
- Interventions
- Device: T-jet® containing TevTropin®Procedure: TevTropin® needle-syringe injection method
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT00990340
Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: Placebo Nasal Aerosol
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 529
- Registration Number
- NCT00988247
- Locations
- 🇺🇸
Teva Clinical Sudy Site, Oxford, Alabama, United States
🇺🇸Teva Clinical Study Site, West Allis, Wisconsin, United States
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 839
- Registration Number
- NCT00988052
- Locations
- 🇧🇬
Teva Investigational Site 5904, Sofia, Bulgaria
🇨🇦Teva Investigational Site 1132, Bedford, Nova Scotia, Canada
🇬🇪Teva Investigational Site 8100, Tbilisi, Georgia
Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 446
- Registration Number
- NCT00982150
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
Phase 2
Completed
- Conditions
- Multiple System Atrophy
- Interventions
- Drug: placebo
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT00977665
- Locations
- 🇺🇸
Teva Investigational Site 1004, Irvine, California, United States
🇺🇸Teva Investigational Site 1006, Sunnyvale, California, United States
🇺🇸Teva Investigational Site 1061, Boca Raton, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath